Entity

Time filter

Source Type

Rosh Ha'ayin, Israel

Patent
Beta-O2 Technologies | Date: 2014-03-27

An implantable medical system that comprises a gas unit for supplying gas that is essentially oxygen and at least one functional cells unit configured to receive oxygen from the gas unit so as to maintain the cells in a viable condition. The cells unit is flexible. Several embodiments are disclosed.


Trademark
Beta-O2 Technologies | Date: 2011-06-29

Medical devices, namely, islets of Langerhans implants consisting primarily of living cells and consisting in part of artificial materials. Medical devices, namely, islets of Langerhans implants consisting primarily of artificial materials and consisting in part of living cells.


Patent
Beta-O2 Technologies | Date: 2011-06-06

A system is provided, including a plurality of donor cells and a first alginate structure that encapsulates the plurality of donor cells. The first alginate structure has a guluronic acid concentration of between 64% and 74%. The system additionally includes a second alginate structure that surrounds the first alginate structure, the second alginate structure having a mannuronic acid concentration of between 52% and 60%. A selectively-permeable membrane is coupled at least in part to the second alginate structure. Other embodiments are also described.


Patent
Beta-O2 Technologies | Date: 2014-08-29

Apparatus is provided, including a housing configured for insertion into a body of a subject; at least one oxygen reservoir disposed within the housing; and at least one layer of transplanted cells, disposed within the housing; and gaseous oxygen disposed within the at least one oxygen reservoir. Other embodiments are also described.


Neufeld T.,Beta-O2 Technologies | Ludwig B.,University Hospital Carl Gustav Carus | Barkai U.,University Hospital Carl Gustav Carus | Barkai U.,Beta-O2 Technologies | And 21 more authors.
PLoS ONE | Year: 2013

Developing a device that protects xenogeneic islets to allow treatment and potentially cure of diabetes in large mammals has been a major challenge in the past decade. Using xenogeneic islets for transplantation is required in light of donor shortage and the large number of diabetic patients that qualify for islet transplantation. Until now, however, host immunoreactivity against the xenogeneic graft has been a major drawback for the use of porcine islets. Our study demonstrates the applicability of a novel immunoprotective membrane that allows successful xenotransplantation of rat islets in diabetic minipigs without immunosuppressive therapy. Rat pancreatic islets were encapsulated in highly purified alginate and integrated into a plastic macrochamber covered by a poly-membrane for subcutaneous transplantation. Diabetic Sinclair pigs were transplanted and followed for up to 90 days. We demonstrated a persistent graft function and restoration of normoglycemia without the need for immunosuppressive therapy. This concept could potentially offer an attractive strategy for a more widespread islet replacement therapy that would restore endogenous insulin secretion in diabetic patients without the need for immunosuppressive drugs and may even open up an avenue for safe utilization of xenogeneic islet donors. © 2013 Neufeld et al.

Discover hidden collaborations